Sutimlimab

Records for this ingredient, by country (identity only).

ATC L04AJ04 · 5 markets · 5 records

Sutimlimab 5 markets · 5 records Forms
Filters

US 1 records · 1 shown of 1 Source openFDA NDC Directory · Data as of 2026-10-23

  • 50 mg per mL / per unit basis not statedinjectionEnjaymo

ES 1 records · 1 shown of 1 Source CIMA (AEMPS) · Data as of live

JP 1 records · 1 shown of 1 Source 厚生労働省 薬価基準収載品目リスト · Data as of 2026-11-01

  • 1100 mg/22 mLinjectionエジャイモ点滴静注1.1g

EU 1 records · 0 shown of 0 Source European Commission · Data as of 2026-11-03 · some records have no stated strength

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商

FR 1 records · 1 shown of 1 Source Base de données publique des médic · Data as of 2026-11-03

  • 50 mg/1 mLinjectionENJAYMO 50 mg/ml, solution pour perfusion also in ES

Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.